The Complications ofAntilymphocyte Therapy Antilymphocyte serum (ALS) or the purified antilymphocyte globulin (ALG) is coming into increasing use in clinical medicine because of its ability to produce a selective depression of cellular immunity while leaving humoral antibody production intact (James & Anderson 1968) . The facts that it is a potent immunosuppressive of this kind, that it is highly immunogenic, and that in organ transplantation it has had to be combined with other agents, have all complicated its use. The major limitation in the use of ALS has been the production and standardization of products suitable for use in man. The large quantities required in clinical practice have meant that most ofit has had to be produced by immunizing horses with human lymphoid tissues; latterly, mostly with thymus or thoracic duct lymphocytes. I shall not discuss the difficulties of its production, or the assay of its potency, except where these influence the side-effects of its administration.
These side-effects may be broadly divided into complications of the interaction of antibody with its antigen, and the results of the specific cellmediated immunosuppression produced.
Side-effects ofImmune Complex Formation
Local effects: The site of an intramuscular injection of ALS or ALG is one where the antibody present in the preparation may react with antigens on the patient's tissues, or with circulating proteins. Injection is accompanied very regularly by pain which lasts for one to two hours afterwards. Some workers have said that the pain decreases with use, and others the reverse, but everyone is agreed that pain at the local site is a very big problem with intramuscular injection. Whereas normal horse serum will not produce a local skin reaction in an unsensitized recipient, ALS or ALG produces an immediate reaction. The same process presumably occurs after intramuscular injection. The local reaction of the ALG with tissue antigens excites the release of pharmacological mediators of inflammation. Some diminution of the local reaction can be achieved by the use of antihistamines. Large daily doses of corticosteroids which may be given in association with the ALS do not abolish the reaction. In some recent preliminary work inhibitors of kinin release show some promise in combination with antihistamines. If an ALS were used which only had antibody directed against determinants on lymphoid tissues, and the lymphoid cells were eliminated from the injection sites by its continued use, some diminution in the local reaction might be expected as the antigen disappeared. This may explain the findings of some workers that pain decreases on continued use. General effects: Pain at the site of injection, and the difficulty of giving adequate doses in volumes acceptable for local injection, have resulted in a change toward the use of intravenous medication. This produces its special side-effects, as well as the general problem of anaphylaxis by any route.
Many preparations of ALS contain material amounts of antibody to plasma proteins. After absorption with red cells, and sometimes plasma protein, they may also contain soluble immune complexes. After interaction of the antibody with proteins in the blood the complexes may produce immune complex nephritis, or other manifestations of immune complex disease such as joint involvement. The development of proteinuria, and the deposition of immune complexes of the xenogeneic immunoglobulin on the basement membrane of the glomerular capillaries, may occurr when the ALG or ALS is given intravenously in animals, but may also occur with subcutaneous injection (Lance 1968 ). This is an obviously undesirable complication, particularly in renal transplantation. It has occurred in man, with preparations which have had detectable amounts of antiprotein antibody. When isotopically-labelled material is given locally the complexes can be demonstrated in the draining lymph node more readily than in the kidney (Carraz 1969, personal communication) .
ALG is highly immunogenic to the recipient (Lance & Dresser 1967) so that it might be thought that the development of antibody to the foreign horse protein might cause its deposition in the kidney. The finding that local administration does not readily produce renal lesions, though the ALG is still effective, suggests that the host's response is not important in the production of the renal deposition of xenogeneic protein, but still might conceivably play a part in renal damage by analogy with the autologous phase of experimental glomerulonephritis (Feldman et al. 1963) . Further work on the renal lesions produced by intravenous ALG in recipients made tolerant to the foreign protein is necessary before the importance of the host response in the production of renal damage can be assessed. Anaphylaxis: Acute anaphylactic reactions to the continued administration of ALS or ALG occur commonly. In one patient who had previously demonstrated sensitivity to horse protein a rapid anaphylactic death followed the first injection. The acute reactions occurring within an hour of injection, though alarming, respond well to standard treatment, and are ameliorated by prior 1068 Proc. roy. Soc. Med. Volume 63 October 1970 28 administration of antihistamines and the basal corticosteroid therapy which many patients have received.
The frequency ofreactions is difficult to predict, but shows a rough correlation with the level of heterophile antibodies in the patient. Recently more attempts have been made to make the patient tolerant to the xenogeneic proteins before starting the course of ALG, since it has been found that the reactions apparently do not occur to the contaminating xenogeneic proteins alone, but may be caused by the immunoglobulin which must be in the preparation.
The frequency of reactions with long courses of ALG has often led to termination of the course, or to the use of ALG from other species, when sensitivity to one species has occurred.
Side-effects ofImmunosuppression
The clinical use of ALG has been largely in organ transplantation, where its efficacy at preventing cellular immunity looked very promising. The fact that the late effects of transplantation immunity do not appear to be due to cellular immunity, but rather to the presence of humoral antibody has meant that ALG has not been used alone in organ transplantation in man. In animals, treatment with ALS alone has resulted in the development of lesions in the glomerular capillaries of renal transplants (Pichlmayr et al. 1968 ). Thus the complications of immunosuppression in ALGtreated patients are a result of combined therapy. It is known that infections with 'opportunist invaders' are common where the standard combination of azathioprine and steroids is used, and that steroid treatment alone may result in many of these infections. Specific suppression, or failure of cellular immunity in man or animals, appears to be associated with a particular susceptibility to virus infections. These are common with the use of azathioprine and steroids. Several centres have reported trouble with herpes simplex virus when ALG is used in addition.
Azathioprine is known to increase the incidence of neoplasia in animals (Casey 1968 ). This agent, although effective in suppressing cellular immunity, also affects humoral immune responses. ALS has been shown to increase the incidence of lymphomas in mice. It might be thought that interference with the ability to control virus infections and hence murine viral oncogenesis was the explanation of this. Recently, however, it has been reported that the latent period was shortened, and the incidence of tumours increased, by ALS treatment of animals in' which chemical carcinogenesis occurred (Cerilli & Treat 1969) .
In man tumours have occurred in patients treated with ALS or ALG, but they are of course known also to occur in patients treated with azathioprine and steroids (McKhann 1969) . It is not at present possible to say whether the incidence is altered by the addition of ALG. If ALG is used alone to treat diseases other than transplantation immunity, a better assessment of the risk will be available. Azathioprine, although carcinogenic, possesses an antitumour action; it may not be as effective in producing measurable oncogenesis as a purely immunosuppressive agent such as ALG.
It can be seen that some of the problems of studying the specific side-effects ofALG in clinical use are complicated by its use in combined therapy. This is necessarily so in organ transplantation. From its possible use in immune diseases of a purely cellular immune character, it will be possible to state more certainly the nature of these risks. In the meantime the use of material with as little nonspecific antibody as possible, in recipients tolerant to xenogeneic protein, will do much to diminish the obvious specific side-effects.
Professor H I Winner, Dr K D Bagshawe, Dr J C Coleman and Dr Anne Gerken (Department ofMicrobiology, Charing Cross Hospital Medical School, London WC2N4DW)
Microbiological Aspects of Cytotoxic Drug Therapy
The microbiological problem is that of keeping patients as free from infection as possible.
Methods ofIsolation
Various methods of isolation are available, such as specially built units or plastic isolators. Whatever method is adopted, a regime has to be devised for the surveillance of patients, staff and environment. Every detail of the regime should be made clear to all concerned and rigidly enforced even though the rationale of some of the measures is likely, in the present state of our knowledge, to be dubious and their efficacy unproved or unprovable. All those concerned with surveillance must
